Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
（2024年1月15日）安斯泰来今天宣布，赵萍女士即日起正式就任安斯泰来中国区总裁，她将成为安斯泰来全球市场管理团队的一员，向首席商务官Claus...
·关键性确证试验结果发现，与标准含铂化疗相比，enfortumab vedotin + pembrolizumab联合疗法显著延长了总生存期和无进展生存期...
2023年11月17日，安斯泰来中国与公益组织“有爱有未来”携手，在北京大兴区爱心希望学校举办了一场别开生面的公益活动——2023安斯泰来急救包捐
–与化疗相比，接受enfortumab vedotin 联合pembrolizumab治疗的患者死亡风险降低了53% – –与化疗相比，enfortumab vedotin 与...
Read more about 突破性的EV-302临床研究显著延长了接受enfortumab vedotin-ejfv和 pembrolizumab一线治疗晚期膀胱癌患者的总生存期和无进展生存期
Follow China news
